Koppikar Utpal 4
4 · Atara Biotherapeutics, Inc. · Filed Mar 3, 2022
Insider Transaction Report
Form 4
Koppikar Utpal
Chief Financial Officer
Transactions
- Award
Common Stock
2022-03-01+61,235→ 216,937 total - Sale
Common Stock
2022-03-01$9.86/sh−2,272$22,393→ 214,665 total - Award
Employee Stock Option (Right to Buy)
2022-03-01+115,107→ 115,107 totalExercise: $10.21Exp: 2032-02-28→ Common Stock (115,107 underlying) - Sale
Common Stock
2022-03-01$9.86/sh−1,491$14,697→ 213,174 total
Footnotes (4)
- [F1]These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
- [F2]Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
- [F3]The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
- [F4]1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.